The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...

Johnson East took Bear in for his shot during his first pediatrician appointment. “He handled it very well,” she remembers. “We didn’t see any side effects with him. We were walked through the side ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible ...

In older adults, RSV is a common cause of a lung disease which can cause life-threatening pneumonia. The RSV vaccine can help ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters. HealthDay News — For ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

During the third quarter, sales of GSK’s shingles vaccine dropped by 7% compared to the same period in 2023, while sales of its shot for respiratory syncytial virus, Arexvy, plunged by 72% year ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

data-text="AIM Vaccine's heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval" data-link=" Vaccine's heavyweight single-product mRNA RSV Vaccine obtained the clinical ...